Subscribe To
SESN / SESEN BIO, INC. (SESN) INVESTOR LAWSUIT FILING DEADLINE: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Sesen Bio
SESN News
By Zacks Investment Research
November 30, 2022
SESEN BIO, INC. (SESN) Upgraded to Buy: What Does It Mean for the Stock?
SESEN BIO, INC. (SESN) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. more_horizontal
By 24/7 Wall Street
November 22, 2022
Bradley Louis Radoff Discloses Activist Position in SESN / Sesen Bio
Fintel reports that Radoff Bradley Louis has filed a 13D form with the SEC disclosing ownership of 6,000,000 shares of Sesen Bio Inc (SESN). more_horizontal
By Zacks Investment Research
July 19, 2022
Sesen (SESN) Halts Bladder Cancer Drug Development, Stock Down
Sesen Bio (SESN) decides to pause the development of Vicineum in the United States. It also ended its 2016 licensing agreement with Roche in exchange more_horizontal
By Benzinga
July 18, 2022
Why Shares Of Sesen Bio Are Down 28% Today
Sesen Bio Inc (NASDAQ: SESN) shares are trading lower by 28.9% at $0.66 Monday morning after the company announced that it has made the decision to v more_horizontal
By Benzinga
July 18, 2022
Sesen Bio Pauses Clinical Development Of Its Lead Bladder Cancer Candidate In US
Based on a thorough reassessment Sesen Bio Inc (NASDAQ: SESN) has decided to voluntarily pause further development in the U.S. of its lead asset, more_horizontal
By PennyStocks
June 9, 2022
Top Penny Stocks To Buy? 4 Biotech Stocks To Watch Now
Biotech penny stocks to watch in June. The post Top Penny Stocks To Buy? more_horizontal
By PennyStocks
April 14, 2022
Best Penny Stocks To Buy Now? 5 Stocks Under $1 To Watch In April
Penny stocks under $1 to watch right now. The post Best Penny Stocks To Buy Now? more_horizontal
By Benzinga
December 9, 2021
Sesen Bio To Conduct Additional Trial For Potential Resubmission Of Vicineum In Bladder Cancer
Sesen Bio Inc (NASDAQ: SESN) has outlined its anticipated regulatory path forward for Vicineum for BCG-unresponsive non-muscle invasive bladder can more_horizontal